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Background: Polymorphisms of Arylamine N-acetyltransferase (NAT) that contribute to diverse susceptibilities of
some autoimmune diseases are also linked to the metabolism of several drugs including sulfasalazine (SSZ). The
aim of this study was to investigate the distribution of NAT polymorphisms in Han Chinese patients with ankylosing
spondylitis (AS) and their correlation to sulfasalazine-induced adverse drug reactions (ADRs).
Methods: Arylamine N-acetyltransferase 1 (NAT1) and arylamine N-acetyltransferase 2 (NAT2) genotypes were
determined in 266 AS patients who received SSZ treatment and 280 healthy controls. The correlation between NAT
polymorphisms and SSZ-induced ADRs was analyzed.
Results: The co-occurrence frequency of NAT2 fast acetylator genotype and NAT1*10/NAT1*10 genotype was lower
in AS patients than in controls. No positive correlations were detected between NAT polymorphisms and AS
clinical features. The prevalence of SSZ-induced ADRs and drug withdrawal was 9.4% and 7.1%, respectively. The
frequencies of overall ADRs, dose-related ADRs, and termination of drug treatment because of intolerance were
higher in the NAT2 slow acetylator genotype carriers than in the fast-type carriers and in those with co-existence of
NAT1 and NAT2 slow acetylator genotypes. Furthermore, the ADRs emerged earlier in the AS cases carrying both
NAT1 and NAT2 slow acetylator genotypes.
Conclusions: The prevalence of co-occurring NAT2 fast acetylator genotype and NAT1*10/NAT1*10 genotype was
lower in AS patients than in controls. The NAT2 slow acetylator genotype and co-existing NAT1 and NAT2 slow
acetylator genotypes appear to be associated with higher risks of SSZ-induced ADRs.
Keywords: Arylamine N-acetyltransferases, Genetic polymorphism, Sulfasalazine, Ankylosing spondylitis, Adverse
drug reactionsBackground
Sulfasalazine (SSZ) is one of the disease-modifying anti-
rheumatic drugs (DMARDs) and has been widely used
for the treatment of ankylosing spondylitis (AS) in China
for years [1]. Though the efficacy of SSZ in treating AS
is still under debate, Chinese rheumatologists prefer to
prescribe SSZ for the treatment of AS because of its
good cost-effectiveness ratio. Nevertheless, the therapy is* Correspondence: qyzeng@stu.edu.cn
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unless otherwise stated.often terminated in about 14–38% of AS patients receiv-
ing SSZ treatment because of adverse drug reactions
(ADRs) [2-4]. There is currently no effective method of
identifying a patient’s susceptibility to SSZ-induced ADRs.
Thus, predicting the therapeutic response of AS patients
to SSZ is of great importance for individualized therapies
of AS.
SSZ is constituted by 5-aminosalicylic acid (5-ASA)
and sulfapyridine (SP). SP is considered to be an active
component for the therapy of AS [5], and is related to
ADRs such as nausea, vomiting, and headache [6], while
5-ASA is effective for the treatment of inflammatory. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7]. When orally administered, SSZ is metabolized into
SP and 5-ASA in the presence of the gut microbiota
[8,9]. SP is almost completely absorbed and metabolized
to N-acetyl-SP predominantly by hepatic arylamine N-
acetyltransferase 2 (NAT2), while only about 20–30% of
5-ASA is absorbed and metabolized to N-acetyl-5-ASA
by arylamine N-acetyltransferase 1 (NAT1), the rest be-
ing eliminated in the feces [9,10]. Therefore, arylamine
N-acetyltransferases (NATs) play an important role in
the metabolism of SP and 5-ASA.
Humans have two functional NAT genes (NAT1 and
NAT2) and a pseudogene (NATP), all found on chromo-
some 8p22 [11]. Genetic mutations of NAT1 and NAT2
result in amino acid substitutions of their protein prod-
ucts, and may lead to altered gene expression and activity
of the NAT enzyme [11-14]. These changes were shown
to contribute to increased susceptibility to a range of dis-
orders including autoimmune diseases [15-20] and carcin-
omas [21-24], but were also linked to the differences in
the ability to N-acetylate certain drugs including SSZ
[6,10,25-29]. In this study, we investigated the genotypes
of the two human NATs in Han Chinese patients with AS
versus healthy controls and also the potential correlation
between NAT polymorphisms and SSZ-induced ADRs.
Methods
Subjects
Two hundred and sixty-six consecutive cases of AS from
the First Affiliated Hospital of Shantou University Medical
College were studied during the period of 2004–2010. All
patients were diagnosed based on the Modified New
York Criteria of AS [30]. All patients were treated with
SSZ at a dose of 1.5–3.0 g/day (Shanghai Zhongxi Sunve
Pharmaceutical Co., Ltd, China). Non-steroidal anti-
inflammatory drugs were prescribed as needed. Two
hundred and eighty healthy volunteers served as the
healthy controls. All subjects were Han Chinese residing
in Shantou, China. This study was approved by the Insti-
tutional Ethics Committee of Shantou University Medical
College, and written informed consent was obtained from
all participants.
Determination of NAT genetic polymorphisms
Genomic DNA was extracted from peripheral blood
samples with the QIAamp Blood Kit (QIAGEN, Hilden,
Germany) and stored at −80°C. Genetic polymorphisms of
NAT1 (NAT1*4, NAT1*3, NAT1*10, NAT1*11) and NAT2
(NAT2*4, NAT2*5, NAT2*6, NAT2*7) were determined
using the polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method [24,31]. The
NAT genotypes of a number of samples were confirmed
through direct DNA sequencing for quality control pur-
poses. Subjects were classified as NAT1 fast acetylatorgenotype carriers (those with at least one NAT1*10 allele)
or NAT1 slow acetylator genotype carriers (those without
NAT1*10 allele) [24]. Individuals carrying at least one
wild-type allele (NAT2*4 allele) were classified as NAT2
fast acetylator genotype carrier, and those carrying the
mutant allele (NAT2*5, *6, *7) were classified as NAT2
slow acetylator genotype carriers [32].
Observation of clinical features
Clinical features observed included age of onset, duration
of disease, joint involvement (classified into two types:
axial joint involvement only, and both axial and peripheral
joint involvements), incidence of radiological hip involve-
ment, and HLA-B27 status.
Assessment of ADRs
All patients were followed up for more than 2 years and
SSZ-induced ADRs were monitored. ADRs and severe
ADRs were defined according to the criteria proposed
by Edwards et al. [33]. ADRs were classified into six
types: dose-related (Augmented), non-dose-related (Bi-
zarre), dose-related and time-related (Chronic), time-
related (Delayed), withdrawal (End of use), and failure of
therapy (Failure). The causality assessment of suspected
ADRs was determined as described previously [33]. ADRs
were classified as being “certain”, “probable”, “possible”,
“unlikely”, “conditional”, and “unassessable”. All ADRs
noted in this study were “certain”, “probable”, or “possible”.
Statistical analysis
Data were analyzed using SPSS 19.0 statistical software.
Departure from the Hardy–Weinberg equilibrium was
tested by the chi-squared test. Frequencies of the alleles,
genotypes, acetylator genotypes, and co-occurrence of
NAT1 with NAT2 acetylator genotypes in each group
were compared using chi-squared test or the Fisher’s
exact test as appropriate. Age of onset and duration of
disease in each group were compared using t-test, one-
way ANOVA test or Kruskal Wallis test as appropriate.
Odds ratio (OR) and a 95% confidence interval (95% CI)
were estimated from logistic regression models to test
for associations between the risk of SSZ-induced ADRs
and the NAT acetylator genotypes. Binary logistic regres-
sion analysis was used to identify the variables (NAT
acetylator genotype, dose, age, sex, and NSAIDs combin-
ation) that provided an important contribution towards
the variability of SSZ-induced ADRs and to adjust for
confounding variables by analysis of covariates. The preva-
lence of drug treatment termination because of SSZ-
induced ADRs in each group was compared using the
chi-squared test or the Fisher’s exact test as appropriate.
Differences in the duration of ADRs occurring in each
group were compared using the Mann–Whitney U test.
P < 0.05 was considered statistically significant.
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Subject characteristics
Of the AS patients, 219 were male and 47 were female.
The positive rate of HLA-B27 in patients was 90.2%.
The mean age was 27.8 ± 9.1 years and the mean disease
duration was 6.8 ± 5.7 years. The control group included
221 male and 59 female healthy volunteers with a mean
age of 35.1 ± 10.0 years.NAT polymorphisms in AS patients and healthy controls
The distribution of NAT1 and NAT2 gene polymorphisms
in AS patients and healthy controls is shown in Table 1.
The allele frequencies of both AS patients and healthy con-
trols were consistent with the Hardy–Weinberg equilib-
rium (P > 0.05). No significant differences between the AS
and control group were found for the distribution of al-
leles, genotypes, and acetylator genotypes when NAT1 and
NAT2 polymorphisms were analyzed independently. How-
ever, the co-occurrence frequency of the NAT2 fast acetyla-
tor genotype and NAT1*10/NAT1*10 genotype was lower
in AS patients than in controls (6.4% vs 11.4%, P = 0.04,
OR = 0.53, 95% CI 0.29–0.98).Correlations between NAT polymorphisms and clinical
features of AS
The age of onset, duration of disease, joint involvement
types, incidence of radiological hip involvement, and the
positive rate of HLA-B27 were not significantly different
in each NAT genotype or NAT acetylator genotype group
among the AS patients (P > 0.05).SSZ-induced ADRs
SSZ-induced ADRs occurred in 25 cases (9.4%) of AS
(Table 2). Among these, 16 patients (64.0%) experienced
dose-related ADRs; eight patients (32.0%) experienced
non-dose-related ADRs, and one patient (4.0%) experi-
enced time-related ADR. The dose-related ADRs observed
in this study included nausea, anorexia, abdominal pain,
diarrhea, epigastric discomfort, dizziness, elevation of
serum liver enzyme levels, and chest congestion. Non-dose-
related ADRs included rash, oral ulcer, and leukopenia.
One patient with cacospermia was classified as having
time-related ADR. No serious ADRs were found in the AS
group of patients. SSZ therapy was terminated because of
SSZ-induced ADRs in 19 AS patients (7.1%). Of these, 10
patients (52.6%) withdrew from SSZ therapy because of
dose-related ADRs; eight patients (42.1%) because of non-
dose-related ADRs, and one patient (5.3%) because of
time-related ADR. The mean duration of SSZ therapy
from the time when the first ADR occurred was 19 days
(range 3–450 days). Most ADRs occurred within 12 weeks
after the start of SSZ treatment (23 cases, 92.0%).Correlations of NAT polymorphisms and SSZ-induced ADRs
Correlations between NAT acetylator genotypes and
SSZ-induced ADRs are shown in Table 3. The incidence
of overall ADRs in patients carrying the NAT2 slow acet-
ylator genotype was 18.5% (10/54) and was significantly
higher than patients carrying the NAT2 fast acetylator
genotype (7.1%, 15/212, P = 0.013, OR = 2.99, 95% CI
1.26-–7.09). The incidence of dose-related ADRs in pa-
tients carrying the NAT2 slow acetylator genotype was
also higher than in patients carrying the fast acetylator
genotype (16.7% vs 3.3%, P = 0.002, OR = 5.17, 95% CI
1.79-–14.92). No significant difference in the incidence
of non-dose-related ADRs was found between the NAT2
fast and NAT2 slow acetylator genotype groups (3.3% vs
1.9%, P > 0.05). The prevalence of drug treatment termin-
ation owing to ADRs or dose-related ADRs was higher in
the NAT2 slow acetylator genotype carriers than in the
fast-type carriers (14.8% vs 5.2%, P = 0.032 and 13.0% vs
1.4%, P = 0.001, respectively).
The incidences of overall ADRs, dose-related ADRs,
and non-dose-related ADRs in patients carrying the NAT1
fast acetylator genotype were 8.1% (11/136), 4.4% (6/136),
and 3.7% (5/136) respectively, similar to 10.8% (14/130),
7.7% (10/130), and 2.3% (3/130) in patients carrying the
NAT1 slow acetylator genotype (P > 0.05). The prevalence
of drug treatment termination owing to overall ADRs or
dose-related ADRs was slightly higher in the NAT1 slow
acetylator genotype carriers than in the fast-type carriers
(8.5% vs 5.9%, and 5.4% vs 2.2%, respectively). However,
the difference was not significant (P > 0.05).
The incidences of both overall ADRs and dose-related
ADRs were higher in patients carrying both the NAT1
slow acetylator genotype and the NAT2 slow acetylator
genotype than in the other carriers (26.3% vs 6.6%,
P < 0.001, OR = 5.07, 95% CI 2.08–12.37 and 23.7% vs
3.1%, P < 0.001, OR = 9.52, 95% CI 3.20–28.30). The
prevalence of drug treatment termination owing to over-
all ADRs or dose-related ADRs was also higher in the car-
riers of both NAT1 slow acetylator genotype and NAT2
slow acetylator genotype than in the other carriers (21.1%
vs 4.8%, P = 0.002 and 18.4% vs 1.3%, P < 0.001, respect-
ively). The mean duration of SSZ treatment when the first
ADR occurred in patients carrying both the NAT1 slow
acetylator genotype and the NAT2 slow acetylator geno-
types was 8 days (range 3–128 days), shorter than that of
33 days (range 10–450 days) in the carriers of other acety-
lator genotypes (P = 0.003). No significant differences in
the frequencies of non-dose-related ADRs were found
among carriers of any NAT1 and NAT2 acetylator geno-
type combinations (P > 0.05).
Only one patient was identified that experienced time-
related ADR and carried NAT1 slow acetylator (NAT1*3/
NAT1*3) and NAT2 fast acetylator (NAT2*4/NAT2*6)
genotypes.
Table 1 Distribution of NAT polymorphisms in AS patients and healthy controls
Alleles/Genotypes/Acetylator genotypes AS HC χ2 P
N % N %
NAT1 Alleles NAT1*4 268 50.4 261 46.6 1.55 0.21
NAT1*3 101 19.0 108 19.3 0.02 0.90
NAT1*10 159 29.9 188 33.6 1.71 0.19
NAT1*11 4 0.7 3 0.5 - 0.72*
Total 532 560
NAT1 Genotypes NAT1*4/NAT1*4 75 28.2 65 23.2 1.78 0.18
NAT1*4/NAT1*3 39 14.7 48 17.1 0.63 0.43
NAT1*4/NAT1*10 77 28.9 80 28.6 0.01 0.92
NAT1*4/NAT1*11 2 0.8 3 1.1 - 1.00*
NAT1*3/NAT1*3 14 5.2 14 5.0 0.02 0.89
NAT1*3/NAT1*10 34 12.8 32 11.4 0.24 0.63
NAT1*3/ NAT1*11 0 0 0 0 - -
NAT1*10/NAT1*10 23 8.6 38 13.6 3.33 0.07
NAT1*10/NAT1*11 2 0.8 0 0 - -
NAT1*11/NAT1*11 0 0 0 0 - -
Total 266 280
NAT1 Acetylator Genotypes Fast 136 51.1 150 53.6 0.33 0.57
Slow 130 48.9 130 46.4
Total 266 280
NAT2 Alleles NAT2*4 310 58.3 340 60.7 0.68 0.41
NAT2*5 18 3.4 18 3.2 0.02 0.88
NAT2*6 134 25.2 129 23.0 0.69 0.41
NAT2*7 70 13.1 73 13.1 0.00 0.95
Total 532 560
NAT2 Genotypes NAT2*4/NAT2*4 98 36.8 110 39.3 0.35 0.56
NAT2*4/NAT2*5 9 3.4 10 3.6 0.01 0.91
NAT2*4/NAT2*6 70 26.3 71 25.4 0.07 0.80
NAT2*4/NAT2*7 35 13.2 39 13.9 0.07 0.79
NAT2*5/NAT2*5 0 0 1 0.4 - -
NAT2*5/NAT2*6 6 2.3 2 0.7 - 0.17*
NAT2*5/NAT2*7 3 1.1 4 1.4 - 1.00*
NAT2*6/NAT2*6 18 6.8 18 6.4 0.03 0.87
NAT2*6/NAT2*7 22 8.2 20 7.1 0.24 0.62
NAT2*7/NAT2*7 5 1.9 5 1.8 - 1.00*
Total 266 280
NAT2 Acetylator Genotypes Fast 212 79.7 230 82.1 0.53 0.47
Slow 54 20.3 50 17.9
Total 266 280
NAT2 fast acetylator genotype plus NAT1*10/NAT1*10 17 6.4 32 11.4 4.24 0.04
*Results of Fisher’s exact test; AS = Ankylosing Spondylitis; HC = healthy control; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2;
N = Number; χ2 = Chi-squared test.
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Table 2 Clinical features and NAT polymorphisms in 25 AS patients who experienced SSZ-induced ADRs





Genotypes Acetylatorgenotypes Genotypes Acetylatorgenotypes
Dose-related Case 1 3.0 Nausea No NAT2*4/NAT2*7 Fast NAT1*10/NAT1*10 Fast
Case 2 3.0 Nausea,
anorexia
No NAT2*4/NAT2*5 Fast NAT1*3/NAT1*10 Fast
Case 3 1.5 Abdominal
pain
Yes NAT2*4/NAT2*6 Fast NAT1*4/NAT1*10 Fast
Case 4 3.0 Diarrhea Yes NAT2*7/NAT2*7 Slow NAT1*4/NAT1*4 Slow
Case 5 3.0 Diarrhea No NAT2*5/NAT2*7 Slow NAT1*4/NAT1*4 Slow
Case 6 3.0 Epigastric
discomfort
No NAT2*4/NAT2*4 Fast NAT1*4/NAT1*10 Fast
Case 7 1.5 Epigastric
discomfort
Yes NAT2*4/NAT2*7 Fast NAT1*4/NAT1*10 Fast
Case 8 1.5 Increase in
transaminases
Yes NAT2*6/NAT2*7 Slow NAT1*4/NAT1*4 Slow
Case 9# 2.25 Increase in
transaminases
Yes NAT2*6/NAT2*7 Slow NAT1*4/NAT1*3 Slow
Case 10 2.25 Dizziness No NAT2*6/NAT2*7 Slow NAT1*3/NAT1*3 Slow
Case 11 1.5 Dizziness Yes NAT2*6/NAT2*6 Slow NAT1*4/NAT1*4 Slow
Case 12 1.5 Dizziness Yes NAT2*5/NAT2*6 Slow NAT1*4/NAT1*4 Slow
Case 13 1.5 Dizziness Yes NAT2*4/NAT2*7 Fast NAT1*10/NAT1*10 Fast
Case 14 1.5 Dizziness Yes NAT2*6/NAT2*6 Slow NAT1*4/NAT1*4 Slow
Case 15 3.0 Dizziness No NAT2*4/NAT2*4 Fast NAT1*4/NAT1*4 Slow
Case 16 1.5 Chest
congestion
Yes NAT2*5/NAT2*6 Slow NAT1*4/NAT1*3 Slow
Non-dose-
related
Case 17 2.25 Leukopenia Yes NAT2*4/NAT2*6 Fast NAT1*4/NAT1*4 Slow
Case 18 1.5 Rash Yes NAT2*6/NAT2*6 Slow NAT1*4/NAT1*4 Slow
Case 19 1.5 Rash Yes NAT2*4/NAT2*6 Fast NAT1*3/NAT1*10 Fast
Case 20 1.5 Rash Yes NAT2*4/NAT2*6 Fast NAT1*4/NAT1*11 Slow
Case 21 3.0 Rash Yes NAT2*4/NAT2*4 Fast NAT1*4/NAT1*10 Fast
Case 22 3.0 Rash Yes NAT2*4/NAT2*4 Fast NAT1*3/NAT1*10 Fast
Case 23 2.25 Oral ulcer Yes NAT2*4/NAT2*4 Fast NAT1*10/NAT1*10 Fast
Case 24 2.25 Oral ulcer Yes NAT2*4/NAT2*4 Fast NAT1*4/NAT1*10 Fast
Time-
related
Case 25# 2.25 Cacospermia Yes NAT2*4/NAT2*6 Fast NAT1*3/NAT1*3 Slow
*ADRs were classified into six types: dose-related, non-dose-related, dose-related and time-related, time-related, withdrawal (End of use), and failure of therapy;
#Case 9 was observed to have elevated serum liver enzyme levels at day 138 and case 25 had cacospermia at day 450 after the start of SSZ treatment; ADRs =
Adverse Drug Reactions; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; SSZ = Sulfasalazine.
Hou et al. BMC Pharmacology and Toxicology 2014, 15:64 Page 5 of 8
http://www.biomedcentral.com/2050-6511/15/64Discussion
This study showed that the NAT genotype appeared not
to correlate with the development of AS or the clinical
features of AS such as age of onset, duration of disease,
joint involvements, incidence of radiological hip involve-
ment, or positive status of HLA-B27. However, the fre-
quency of co-occurrence of the NAT2 fast acetylator
genotype and the NAT1*10/NAT1*10 genotype was sig-
nificantly lower in AS patients than in healthy controls
(P = 0.04, OR = 0.53, 95% CI 0.29–0.98). This suggests that
the co-occurrence of the NAT2 fast acetylator genotype
and the NAT1*10/NAT1*10 genotype is likely to reduceone-half the risk of AS in the Chinese Han population. It
was reported that partial linkage disequilibrium exists be-
tween the NAT1*10 allele and the NAT2 fast acetylation
genotype, and a reduced risk for bladder cancer was iden-
tified in carriers of these co-existing genotypes [34]. Be-
cause the sample size of our study was relatively small,
further investigation should be conducted to reveal the
biological significance of the partial linkage disequilibrium
between the NAT1*10 allele and the NAT2 fast acetylation
genotype in the development of AS.
In the current study, the most common SSZ-induced
ADR were gastrointestinal reactions (nausea and diarrhea),
Table 3 Associations between NAT acetylator genotypes and SSZ-induced ADRs
NAT2 acetylator genotype NAT1 acetylator genotype Co-existence of NAT1 and NAT2
acetylator genotypes




Total ADRs 7.1%(15/212) 18.5%(10/54) 8.1%(11/136) 10.8%(14/130) 26.3%(10/38) 6.6%(15/228)
P* 0.013 0.45 <0.001
OR* 2.99 5.07
95% CI* 1.26-7.09 2.08-12.37
Drug therapy termination rate
due to ADRs
5.2%(11/212) 14.8%(8/54) 5.9%(8/136) 8.5%(11/130) 21.1%(8/38) 4.8%(11/228)
P 0.032# 0.41 0.002#
Dose-related ADR 3.3%(7/212) 16.7%(9/54) 4.4%(6/136) 7.7%(10/130) 23.7%(9/38) 3.1%(7/228)
P* 0.002 0.27 <0.001
OR* 5.17 9.52
95% CI* 1.79-14.92 3.20-28.30
Drug therapy termination rate
due to dose-related ADRs
1.4%(3/212) 13.0%(7/54) 2.2%(3/136) 5.4%(7/130) 18.4%(7/38) 1.3%(3/228)
P 0.001# 0.21# <0.001#
Non-dose-related ADR 3.3%(7/212) 1.8%(1/54) 3.7%(5/136) 2.3%(3/130) 2.6%(1/38) 3.1%(7/228)
P* 0.58 0.51 0.88
*Results of binary logistic regression analysis after adjusting for dose, age, sex, and NSAIDs combination; #Results of Fisher’s exact test; OR = odds ratio;
CI = confidence interval; ADRs = Adverse Drug Reactions; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; SSZ = Sulfasalazine.
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serum liver transaminases. Hematological disturbances
(leukopenia) and cacospermia were rarely seen. These
characteristics were similar to those reported in previous
studies [9,35]. It was also reported that most SSZ-induced
ADRs occurred within the first 12 weeks of SSZ treatment
[36]. In our study, most ADRs (92%) also occurred within
the first 12 weeks. However, one patient (case 9) was ob-
served to have elevated serum liver enzyme levels at day
138 and another patient (case 25) had cacospermia at day
450 after the start of SSZ treatment. This indicates it is
important to monitor the ADRs during the first 12 weeks
of SSZ treatment. However, liver function tests need to
be carried out beyond 12 weeks. Morphological examin-
ation and motility tests for sperm are also important for
male patients.
The association between single nucleotide polymor-
phisms (SNPs) and NAT expression has been described in
previous reports [11-14]. For example, 341 T > C (I114T)
and 590G >A (R197Q) reduce NAT2 catalytic activities,
whereas 481C > T (L161L) do not. NAT polymorphisms
linked to the differences in the ability to N-acetylate SSZ
have been identified [6,10,25-29]. However, it is still not
clear whether the genetic variants of NAT1 and NAT2
underlie the patients’ response to SSZ. Previous studies
identified a strong association between NAT2 polymor-
phisms and SSZ-induced ADRs [20,31,37-39] and this
association was thought to have an effect on the efficacy
of SSZ [26,39] . However, others suggested that NAT1 andNAT2 polymorphisms played no roles in predicting re-
sponses to SSZ or related toxicities [40,41]. In our study,
the frequencies of overall ADRs and dose-related ADRs of
SSZ were higher in the NAT2 slow acetylation genotype
group than in the NAT2 fast-type group. The ORs were
2.99 (95% CI 1.26–7.09) and 5.17 (95% CI 1.79–14.92),
respectively, indicating that the NAT2 slow acetylator
genotype may be a risk factor for ADRs, especially the
dose-related ADRs of SSZ. In addition, the prevalence
of SSZ treatment terminations owing to overall ADRs
or dose-related ADRs was also higher in the NAT2 slow
acetylator genotype carriers as compared with that in
the NAT2 fast-type carriers (14.8% vs 5.2%, P = 0.032
and 13.0% vs 1.4%, P = 0.001). In our study, non-dose-
related ADRs only occurred in one patient carrying the
NAT2 slow acetylator genotype. Therefore, it is difficult
to evaluate the contribution of the NAT2 acetylation
genotype to non-dose-related ADRs of SSZ.
The NAT1 function is also widely variable in human
populations, although the effects of its genetic polymor-
phisms are not generally as marked as those of NAT2
[12,13,42]. The current study provided little evidence of
correlation between NAT1 acetylator genotypes and the
risk of SSZ-induced ADRs by NAT1 single-gene analysis.
However, the co-existence of the NAT1 slow acetylator
genotype and the NAT2 slow acetylator genotype conferred
a 5-fold greater risk for overall ADRs, and a 9-fold greater
risk for dose-related ADRs as compared with other acetyla-
tor genotype carriers. The termination of SSZ treatment
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commonly seen in AS patients carrying the NAT1 slow
and NAT2 slow acetylator genotypes. Additionally, the on-
set of ADRs was earlier in patients with co-existing the
NAT1 slow and NAT2 slow acetylator genotypes than that
for other acetylator genotype carriers (8 vs 33 days, P =
0.003). These findings allow the identification of patients at
a possible risk of SSZ-induced ADRs or subsequent termi-
nations of SSZ treatment. It is also important to note that
a multi-gene analysis approach is still worthwhile in phar-
macogenetic studies even if no positive correlations are
found via a single gene analysis.
Similar to the findings of other studies involving Asians
such as Chinese and Japanese populations [19,43], our re-
sults showed the prevalence of the NAT2 slow acetylator
genotype was 20.3% in Han Chinese patients with AS,
which is significantly lower than that reported for Western
populations (40–70%) [13]. This might explain why SSZ-
induced ADRs are much less prevalent among the Chinese
(9.4% in our study population) and the Japanese (11.1%)
[37] as compared with Western populations (22.7-53.5%)
[2,9,35,40]. However, the statistical power is relatively low
because of the low frequency of the NAT2 slow acetylator
genotype in our study population. It is a challenge to
evaluate correlations between NAT polymorphisms and
SSZ-induced ADRs without bias. Thus, studies of multi-
ethnicity and larger populations are required.Conclusions
The co-occurrence of the NAT2 fast acetylator genotype
and the NAT1*10/NAT1*10 genotype is less frequent in
AS patients compared with healthy controls in the Han
Chinese population. The NAT2 slow acetylator genotype
and co-existing NAT1 and NAT2 slow acetylator geno-
types appear to be associated with higher risks of SSZ-
induced ADRs.
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